Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors.
暂无分享,去创建一个
T. Jouary | F. Zerbib | M. Beylot-Barry | A. Taïeb | K. Ezzedine | M. Truchetet | J. Seneschal | T. Schaeverbeke | B. Milpied | D. Laharie | A. Darrigade | M. Beylot‐Barry
[1] J. Gisbert,et al. Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study , 2016, Inflammatory bowel diseases.
[2] A. Steiner,et al. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria. , 2016, Acta dermato-venereologica.
[3] L. Peyrin-Biroulet,et al. Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience , 2015, The American Journal of Gastroenterology.
[4] Leyla J. Ghazi,et al. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease , 2015, Digestive Diseases and Sciences.
[5] L. Guidi,et al. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.
[6] S. Brand,et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment , 2013, Gut.
[7] J. Korzenik,et al. Psoriasis associated with anti‐tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature , 2011, Alimentary pharmacology & therapeutics.
[8] C. Libert,et al. The X chromosome in immune functions: when a chromosome makes the difference , 2010, Nature Reviews Immunology.
[9] S. Lepreux,et al. Cytokine imbalance with increased production of interferon‐α in psoriasiform eruptions associated with antitumour necrosis factor‐α treatments , 2009, The British journal of dermatology.
[10] P. Barachini,et al. Psoriasis Induced by Infliximab in a Patient Suffering from Crohn's Disease , 2009, International journal of immunopathology and pharmacology.
[11] G. Fiorino,et al. Review article: anti TNF‐α induced psoriasis in patients with inflammatory bowel disease , 2009, Alimentary pharmacology & therapeutics.
[12] A. Gottlieb,et al. Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases , 2009, The Journal of dermatological treatment.
[13] J. S. Henning,et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. , 2008, Arthritis and rheumatism.
[14] P. Tak,et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.
[15] M. Lebwohl,et al. Potential complications associated with the use of biologic agents for psoriasis. , 2007, Dermatologic clinics.
[16] M. Martinka,et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. , 2007, Archives of dermatology.
[17] I. Buchan,et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.
[18] P. Jüni,et al. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. , 2005, Rheumatology.
[19] E. Fonseca,et al. Psoriasiform Eruption Induced by Infliximab , 2004, The Annals of pharmacotherapy.
[20] P. V. van Riel,et al. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.
[21] G. Kollias,et al. Tumor necrosis factor biology in experimental and clinical arthritis , 2003, Current opinion in rheumatology.
[22] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[23] D V Cicchetti,et al. Assessing Inter-Rater Reliability for Rating Scales: Resolving some Basic Issues , 1976, British Journal of Psychiatry.
[24] V. Pascual,et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.